.Nature Medicine, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin caused boosted progression-free as well as overall survival, resulting in FDA approval as well as a new procedure possibility for clients.